HC Wainwright Comments on Erasca’s Q3 Earnings (NASDAQ:ERAS)

Erasca, Inc. (NASDAQ:ERAS) – Research analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Erasca in a report released on Tuesday, May 12th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.13) per share for the quarter, down from their previous estimate of ($0.12). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Erasca’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Erasca’s Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.55) EPS, FY2029 earnings at ($0.55) EPS and FY2030 earnings at ($0.33) EPS.

Erasca (NASDAQ:ERAS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48).

ERAS has been the topic of several other research reports. Mizuho lowered their price objective on shares of Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a research report on Tuesday. Stifel Nicolaus lifted their price objective on shares of Erasca from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. JPMorgan Chase & Co. lifted their price objective on shares of Erasca from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 18th. Guggenheim lifted their price objective on shares of Erasca from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a research report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.75.

Erasca Stock Performance

Shares of ERAS stock opened at $10.46 on Thursday. The firm has a market cap of $3.25 billion, a price-to-earnings ratio of -11.25 and a beta of 0.68. Erasca has a 52 week low of $1.06 and a 52 week high of $24.28. The firm’s 50-day simple moving average is $15.41 and its two-hundred day simple moving average is $9.51.

Hedge Funds Weigh In On Erasca

Several large investors have recently modified their holdings of ERAS. AQR Capital Management LLC increased its stake in shares of Erasca by 594.8% in the first quarter. AQR Capital Management LLC now owns 396,202 shares of the company’s stock worth $543,000 after purchasing an additional 339,177 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Erasca by 1.6% in the second quarter. Geode Capital Management LLC now owns 4,835,642 shares of the company’s stock worth $6,143,000 after purchasing an additional 77,790 shares in the last quarter. Creative Planning increased its stake in shares of Erasca by 423.3% in the second quarter. Creative Planning now owns 244,332 shares of the company’s stock worth $310,000 after purchasing an additional 197,637 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of Erasca by 39.1% in the second quarter. New York State Common Retirement Fund now owns 37,360 shares of the company’s stock worth $47,000 after purchasing an additional 10,501 shares in the last quarter. Finally, Invesco Ltd. increased its stake in shares of Erasca by 51.6% in the second quarter. Invesco Ltd. now owns 172,226 shares of the company’s stock worth $219,000 after purchasing an additional 58,643 shares in the last quarter. Hedge funds and other institutional investors own 67.78% of the company’s stock.

Insider Activity

In other news, insider Shannon Morris sold 20,000 shares of Erasca stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $15.04, for a total value of $300,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ebun Garner sold 80,000 shares of Erasca stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $16.40, for a total transaction of $1,312,000.00. Following the completion of the transaction, the insider owned 25,076 shares of the company’s stock, valued at $411,246.40. The trade was a 76.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 14.20% of the stock is owned by company insiders.

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.